# SAFETY DATA SHEET



# SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation

of the mixture

LISKONUM TABLETS

Registration number

LISKONUM CONTROLLED RELEASE TABLETS 450 MG \* ESKALITH CONTROLLED RELEASE **Synonyms** 

TABLETS 450 MG \* QUILONUM SR TABLETS \* QUILONUM 450 MG SR TABLETS \*

QUILONIUM-R TABLETS \* LITHIUM CARBONATE, FORMULATED PRODUCT

Issue date 04-November-2014

Version number

04-November-2014 **Revision date** 

## 1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses Medicinal Product.

> This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant

to medicinal use of the product. In this instance patients should consult prescribing

information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

Uses advised against No other uses are advised.

## 1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK 980 Great West Road

Brentford, Middlesex TW8 9GS UK

UK General Information (normal business hours): +44-20-8047-5000

Email Address: msds@gsk.com Website: www.gsk.com

1.4. Emergency telephone

number

TRANSPORT EMERGENCIES::

UK In-country toll call: +(44)-870-8200418 International toll call: +1 703 527 3887

available 24 hrs/7 days; multi-language response

### **SECTION 2: Hazards identification**

### 2.1. Classification of the substance or mixture

### Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

### Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

# 2.2. Label elements

#### Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Caution - Pharmaceutical agent. See section 11 for additional information on health hazards. 2.3. Other hazards

# **SECTION 3: Composition/information on ingredients**

#### 3.2. Mixtures

Material name: LISKONUM TABLETS

**General information** 

Chemical name % CAS-No. / EC No. REACH Registration No. INDEX No. Notes

LITHIUM CARBONATE < 65 554-13-2 -

209-062-5

Classification: DSD: Repr. Cat. 1;R61, Xn;R22, Xi;R36, R64

**CLP:** Acute Tox. 4;H302, Eye Irrit. 2;H319, STOT SE 3;H335, Repr. 1A;H360FD

POVIDONE 30 < 15 9003-39-8 - -

Classification: DSD: R52/53

CLP: Aquatic Chronic 3;H412

Talc < 10 14807-96-6 -

238-877-9

Classification: DSD: -

CLP: -

Titanium dioxide < 0,25 13463-67-7

236-675-5

Classification: DSD: -

CLP: -

Other components below reportable levels < 20

#### List of abbreviations and symbols that may be used above

CLP: Regulation No. 1272/2008.

DSD: Directive 67/548/EEC.

M: M-factor

vPvB: very persistent and very bioaccumulative substance.

PBT: persistent, bioaccumulative and toxic substance.

#: This substance has been assigned Community workplace exposure limit(s).

**Composition comments** The full text for all R- and H-phrases is displayed in section 16.

## **SECTION 4: First aid measures**

General information In the case of accident or if you feel unwell, seek medical advice immediately (show the label

where possible). Ensure that medical personnel are aware of the material(s) involved, and take

precautions to protect themselves.

4.1. Description of first aid measures

**Inhalation** Move to fresh air. If breathing is difficult, trained personnel should give oxygen. Call a physician if

symptoms develop or persist. Under normal conditions of intended use, this material is not

expected to be an inhalation hazard.

**Skin contact** Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse.

Get medical attention if symptoms occur.

**Eye contact** Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

**Ingestion** If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large

amount does occur, call a poison control centre immediately. Do not induce vomiting without

advice from poison control center.

4.2. Most important symptoms and effects, both acute and

delayed

Direct contact with eyes may cause temporary irritation. Symptoms may include stinging, tearing, redness, swelling, and blurred vision. The following adverse effects have been noted with therapeutic use of this material: anorexia; dry mouth; nausea; vomiting; diarrhoea; tremor; thirst;

mental impairment.

4.3. Indication of any immediate medical attention and special treatment needed

No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.

### **SECTION 5: Firefighting measures**

**General fire hazards**No unusual fire or explosion hazards noted.

5.1. Extinguishing media

Suitable extinguishing

Water. Foam. Dry chemical powder. Carbon dioxide (CO2).

media

Unsuitable extinguishing None known.

media

Material name: LISKONUM TABLETS

SDS MALTA

5.2. Special hazards arising from the substance or mixture During fire, gases hazardous to health may be formed.

5.3. Advice for firefighters

Special protective equipment for firefighters

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Special fire fighting

procedures

Move containers from fire area if you can do so without risk.

Specific methods Use standard firefighting procedures and consider the hazards of other involved materials.

## **SECTION 6: Accidental release measures**

#### 6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Keep out of low areas. Wear appropriate protective equipment and clothing during clean-up. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8.

For emergency responders

Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the SDS.

6.2. Environmental precautions

Avoid discharge into drains, water courses or onto the ground.

6.3. Methods and material for containment and cleaning up Stop the flow of material, if this is without risk. Prevent entry into waterways, sewer, basements or confined areas. Following product recovery, flush area with water.

6.4. Reference to other sections

For personal protection, see section 8. For waste disposal, see section 13 of the SDS.

## **SECTION 7: Handling and storage**

7.1. Precautions for safe handling

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Avoid contact with eyes, Avoid prolonged exposure. Do not taste or swallow. When using, do not eat, drink or smoke. Pregnant or breastfeeding women must not handle this product. Should be handled in closed systems, if possible. Provide adequate ventilation. Wear appropriate personal protective equipment. Wash hands thoroughly after handling. Observe good industrial hygiene practices.

7.2. Conditions for safe storage, including any incompatibilities

Store locked up. Store in original tightly closed container. Store away from incompatible materials (see Section 10 of the SDS).

7.3. Specific end use(s) Medicinal Product.

## **SECTION 8: Exposure controls/personal protection**

#### 8.1. Control parameters

## Occupational exposure limits

G	S	K

Components	Туре	Value	Note
LITHIUM CARBONATE (CAS 554-13-2)	8 HR TWA	400 mcg/m3	
,	OHC	2	Reproductive hazard
alagiaal limit valuas	No higherinal exposure limits noted for	the ingredient(e)	

Biological limit values

No biological exposure limits noted for the ingredient(s).

Recommended monitoring

procedures

Follow standard monitoring procedures.

Derived no-effect level (DNEL) Not available. Not available. Predicted no effect

concentrations (PNECs) Exposure guidelines

8.2. Exposure controls

Appropriate engineering controls

An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. General ventilation normally adequate.

## Individual protection measures, such as personal protective equipment

**General information** Personal protection equipment should be chosen according to the CEN standards and in

discussion with the supplier of the personal protective equipment. Follow all local regulations if

personal protective equipment (PPE) is used in the workplace.

If contact is likely, safety glasses with side shields are recommended. (e.g. EN 166). Not normally Eye/face protection

needed.

Skin protection

For prolonged or repeated skin contact use suitable protective gloves. Select suitable chemical - Hand protection

resistant protective gloves (EN 374) with a protective index 6 (>480min permeation time). Not

normally needed.

- Other Wear suitable protective clothing as protection against splashing or contamination. (EN 14605 for

splashes, EN ISO 13982 for dust). Not normally needed.

Respiratory protection When workers are facing concentrations above the exposure limit they must use appropriate

certified respirators. No personal respiratory protective equipment normally required.

Wear appropriate thermal protective clothing, when necessary. Thermal hazards

Hygiene measures Always observe good personal hygiene measures, such as washing after handling the material

and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. For advice on suitable monitoring methods, seek guidance

from a qualified environment, health and safety professional.

**Environmental exposure controls** 

Hazard guidance and control recommendations Environmental manager must be informed of all major releases.

## **SECTION 9: Physical and chemical properties**

## 9.1. Information on basic physical and chemical properties

**Appearance** 

Solid. Physical state **Form** Tablet. Colour Not available Not available. Odour **Odour threshold** Not available. Not available. Melting point/freezing point Not available. Initial boiling point and boiling Not available.

range

Not available. Flash point Not available. **Evaporation rate** Not available. Flammability (solid, gas) Upper/lower flammability or explosive limits

Flammability limit - lower

(%)

Not available.

Flammability limit - upper

Not available.

Vapour pressure Not available. Vapour density Not available. Not available. Relative density

Solubility(ies)

Not available. Solubility (water) Not available. Solubility (other) **Partition coefficient** 

(n-octanol/water)

Not available.

Not available. **Auto-ignition temperature Decomposition temperature** Not available. Not available. **Viscosity** Not available. **Explosive properties** Not available. Oxidizing properties

9.2. Other information No relevant additional information available.

## **SECTION 10: Stability and reactivity**

10.1. Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport.

Material is stable under normal conditions. 10.2. Chemical stability

10.3. Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Contact with incompatible materials. 10.4. Conditions to avoid

Peroxides, Phenols, 10.5. Incompatible materials

Material name: LISKONUM TABLETS 4365 Version #: 14 Revision date: 04-November-2014 Issue date: 04-November-2014 10.6. Hazardous decomposition products None known. Irritating and/or toxic fumes and gases may be emitted upon the product's

decomposition.

## **SECTION 11: Toxicological information**

**General information** Occupational exposure to the substance or mixture may cause adverse effects.

Information on likely routes of exposure

Inhalation Under normal conditions of intended use, this material is not expected to be an inhalation hazard.

Health injuries are not known or expected under normal use. Skin contact

Health injuries are not known or expected under normal use. Direct contact with eyes may cause Eye contact

temporary irritation.

Health injuries are not known or expected under normal use. Harmful if swallowed. However, Ingestion

ingestion is not likely to be a primary route of occupational exposure.

**Symptoms** Direct contact with eyes may cause temporary irritation. Exposed may experience eye tearing,

redness, and discomfort.

The following adverse effects have been noted with therapeutic use of this material: anorexia; dry

mouth; nausea; vomiting; diarrhoea; tremor; thirst; mental impairment.

### 11.1. Information on toxicological effects

**Acute toxicity** Harmful if swallowed. Expected to be a low hazard for usual industrial or commercial handling by

trained personnel.

**Species Test results** Components LITHIUM CARBONATE (CAS 554-13-2)

Acute

Inhalation

Human >= 1 mg/m3 Respiratory irritation

Oral

LD50 Rat 600 mg/kg

POVIDONE 30 (CAS 9003-39-8)

Acute

Oral

LD50 Rat > 5000 mg/kg

Titanium dioxide (CAS 13463-67-7)

**Acute** 

Inhalation

LC50 Rat 6820 mcg/m3

Oral

Rat LD50 > 24 g/kg

Chronic

Inhalation

LOEC Rat 8,6 mg/m3, 1 years TiO2 accumulated in

> interstitial macrophages, aggregated interstitial cells and particle laden macrophrages in lymphoid tissue.

NOAEC Rat 250 mg/m3, 2 years Highest dose

5 mg/m3, 24 months

Subacute

Inhalation

LOEL Rat 0,1 - 35 mg/m3, 4 weeks Mild macrophage

hyperplasia, no change in bronchio-alveolar lavage fluid.

NOAEC 26 mg/m3, 3 weeks No evidence of Guinea pig

significant inflammation in respiratory tract.

Oral

100000 ppm, 14 Day Dietary study, highest **NOAEL** Rat

dose tested.

Material name: LISKONUM TABLETS

Components Species Test results

Subchronic

Inhalation

LOEC Rat 3,2 - 20 mg/m3, 8 min Accumulation of

TiO2 in macrophages and evidence of

pulmonary inflammation.

\* Estimates for product may be based on additional component data not shown.

**Skin corrosion/irritation** Health injuries are not known or ex

Health injuries are not known or expected under normal use.

Irritation Corrosion - Skin

TITANIUM DIOXIDE 0, Literature data

Result: Non-irritant Species: Guinea pig 0, Literature data Result: Non-irritant Species: Human

Acute dermal irritation; OECD 404, Literature data

Result: Non-irritant Species: Rabbit

Serious eye damage/eye

irritation

Health injuries are not known or expected under normal use. Direct contact with eyes may cause

temporary irritation.

Eye

LITHIUM CARBONATE OECD 405

None known.

Result: Irritant Species: Rabbit

Notes: Literature Reference
TITANIUM DIOXIDE
OECD 405, Literature data
Result: Mild irritant

Species: Rabbit

Respiratory sensitisation

Skin sensitisation

None known. This product is not expected to cause skin sensitisation.

Sensitisation

TITANIUM DIOXIDE 5 % Optimisation Test, Literature data - Vehicle: petrolatum

Result: negative Species: Guinea pig

Test Duration: 48 hour exposure

Patch test, Literature data

Result: negative Species: Human

Germ cell mutagenicity

No data available to indicate product or any components present at greater than 0.1% are

mutagenic or genotoxic.

Mutagenicity

TITANIUM DIOXIDE Ames, Literature data

Result: negative

Micronucleus Assay in vitro, CHO cells, Literature data

Result: negative

Micronucleus Assay in vitro, cultured human peripheral

lymphocytes, Literature data

Result: positive

Syrian Hamster Embryo (SHE) cell transformation assay

Result: negative

WIL2-NS HPRT/ t-Thioguanidine - Human B-Cell

lymphoblastoid, Literature data

Result: positive

Carcinogenicity Not classifiable as to carcinogenicity to humans. Carcinogenic effects are not expected as a result

of occupational exposure.

LITHIUM CARBONATE 0,02 mmol/L, NOAEL

Species: Rat

Notes: Literature Reference 0,5 mg/m3, Literature data

Result: negative Species: Rat

Test Duration: 24 months

0,72 - 14,8 mg/m3, Literature data

Result: negative Species: Mouse

TITANIUM DIOXIDE

Carcinogenicity

TITANIUM DIOXIDE 10 - 250 mg/m3, Dietary study - Literature data.

Result: Inflammation at all doses with alveolar/bronchiolar

adenoma at the highest concentration.

Species: Rat

Test Duration: 24 months 25000 - 50000 ppm, Dietary study

Result: negative Species: Mouse

25000 - 50000 ppm, Dietary study - Literature data.

Result: negative Species: Rat

7,2 - 14,8 mg/m3, Literature data

Result: Lung tumour Species: Rat

Test Duration: 24 months

### IARC Monographs. Overall Evaluation of Carcinogenicity

POVIDONE 30 (CAS 9003-39-8) Titanium dioxide (CAS 13463-67-7) 3 Not classifiable as to carcinogenicity to humans.

2B Possibly carcinogenic to humans.

Reproductive toxicity

Components in this product have been shown to cause birth defects and reproductive disorders in laboratory animals. These effects are linked only to high doses of this substance; low doses did not produce this adverse effect.

Reproductivity

LITHIUM CARBONATE

10 - 200 mg/kg/day Reproduction/Fertility Study Result: Reduced reproductive capacity, increased pup mortality and delayed post-natal development.

Species: Mouse

Notes: Literature Reference

2 mg/kg/day Fertility, Male, Possibly species-specific.

Result: Inhibition of spermatogenesis.

Species: Rat

Notes: Literature Reference

Clinical use

Result: Cardiovascular malformations.

Species: Human

Notes: Literature Reference

Specific target organ toxicity -

single exposure

Central nervous system.

LITHIUM CARBONATE

Organ: Central nervous system. Notes: Literature Reference

Specific target organ toxicity -

repeated exposure

LITHIUM CARBONATE

Organ: Kidney

Notes: Literature Reference

**Aspiration hazard** Not likely, due to the form of the product.

Mixture versus substance

information

No information available.

Other information Caution - Pharmaceutical agent. Occupational exposure to the substance or mixture may cause

adverse effects.

Kidneys.

# **SECTION 12: Ecological information**

**12.1. Toxicity** Not expected to be harmful to aquatic organisms.

Component	ts		Species	Test results				
LITHIUM CA	LITHIUM CARBONATE (CAS 554-13-2)							
Aq	uatic							
Aci	ute							
Cru	ustacea	EC50	Water flea (Daphnia magna)	1,2 mg/l, 48 hours Static test				
Fis	h	EC50	Rainbow trout (Adult Oncorhyncus mykiss)	9,3 mg/l, 28 days Static renewal test				
POVIDONE	30 (CAS 9003-3	9-8)						
Ace	ute							
		IC50	Activated sludge	> 1000 mg/l, 3 hours Static test				
Aq	uatic							
Ace	ute							
Cru	ustacea	EC50	Water flea (Daphnia magna)	84 mg/l, 48 hours Static test				

Material name: LISKONUM TABLETS

SDS MALTA

Components		Species	Test results	
	NOEC	Water flea (Daphnia magna)	32 mg/l, 48 hours Static test	
Talc (CAS 14807-96-6)				
Aquatic				
Acute				
Fish	EC50	Zebra fish (Adult Brachydanio rerio)	> 100 g/l, 24 hours Static renewal test	
Titanium dioxide (CAS 13463-67-7)				
Aquatic				
Acute				

Water flea (Daphnia magna)

# 12.2. Persistence and

degradability

**Biodegradability** 

Crustacea

Percent degradation (Aerobic biodegradation-inherent)

EC50

POVIDONE 30 0 %, 28 days Modified MITI test, Activated sludge

**12.3. Bioaccumulative potential** No data available.

Partition coefficient

Not available.

n-octanol/water (log Kow)

12.4. Mobility in soilNot available.Mobility in generalNot available.12.5. Results of PBTNot available.

and vPvB assessment

**12.6. Other adverse effects** Not available.

## **SECTION 13: Disposal considerations**

#### 13.1. Waste treatment methods

Residual waste Dispose of in accordance with local regulations. Empty containers or liners may retain some

product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions). Avoid discharge into water courses or onto the ground.

**Contaminated packaging** Empty containers should be taken to an approved waste handling site for recycling or disposal.

Since emptied containers may retain product residue, follow label warnings even after container is

> 1000 mg/l, 48 hours Static test

emptied.

**EU waste code**The Waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

**Disposal methods/information** Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Do not

discharge into drains, water courses or onto the ground. Dispose in accordance with all applicable

regulations.

**Special precautions**Dispose in accordance with all applicable regulations.

## **SECTION 14: Transport information**

#### ADR

Not regulated as dangerous goods.

## IATA

Not regulated as dangerous goods.

### **IMDG**

Not regulated as dangerous goods.

Not regulated as darigerous goods

14.7. Transport in bulk

MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine

according to Annex II of environment. These materials may not be transported in bulk.

MARPOL73/78 and the IBC Code

## **SECTION 15: Regulatory information**

# 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

## **EU** regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Not listed.

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Not listed.

Material name: LISKONUM TABLETS

<sup>\*</sup> Estimates for product may be based on additional component data not shown.

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Not listed

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended

Not listed

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(10) Candidate List as currently published by ECHA

Not listed

### **Authorisations**

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended Not listed.

#### Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended Not listed.

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

## Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Not listed.

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Directive 94/33/EC on the protection of young people at work

Not listed.

**Other regulations**The product is classified and labelled in accordance with EC directives or respective national laws.

This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006.

National regulations Young people under 18 years old are not allowed to work with this product according to the EU

Directive 94/33/EC on the protection of young people at work. Follow national regulation for work

with chemical agents.

15.2. Chemical safety

assessment

No Chemical Safety Assessment has been carried out.

## **SECTION 16: Other information**

**List of abbreviations** Not available.

**References** GSK Hazard Determination

Information on evaluation method leading to the classification of mixture

The classification for health and environmental hazards is derived by a combination of calculation

methods and test data, if available.

Full text of any statements or R-phrases and H-statements under Sections 2 to 15

der Sections 2 to 15 R22 Harmful if swallowed.

R36 Irritating to eyes.

R52/53 Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic

environment.

R61 May cause harm to the unborn child. R64 May cause harm to breastfed babies.

H302 Harmful if swallowed. H319 Causes serious eye irritation. H335 May cause respiratory irritation.

H360FD May damage fertility. May damage the unborn child.

H412 Harmful to aquatic life with long lasting effects.

Material name: LISKONUM TABLETS

SDS MALTA

**Revision information** Product and Company Identification: Product and Company Identification

Composition / Information on Ingredients: Undisclosed Ingredient Statement

Physical & Chemical Properties:

Toxicological Information: **Ecological information:** 

Transport Information: Material Transportation Information

Regulatory Information: Risk Phrases - Class.

**GHS: Classification** 

**Training information** 

Disclaimer

Follow training instructions when handling this material.

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and

the suitability of the material or product for any particular purpose.

Material name: LISKONUM TABLETS

4365 Version #: 14 Revision date: 04-November-2014 Issue date: 04-November-2014